The ARID5B Knockout Jurkat Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population in which the ARID5B gene is disrupted, creating a loss-of-function model. Originating from Jurkat T lymphoblasts, this polyclonal pool enables investigation of ARID5B-mediated transcriptional networks and their relevance to T-cell leukemia. The polyclonal nature preserves genetic heterogeneity, making the cells suitable for bulk assays without clonal selection bias. These cells are supplied as a viable population for downstream applications.
Jurkat cells are an immortalized T-lymphoblast line derived from a 14-year-old male with acute T-cell leukemia, providing a clinically relevant context for leukemia studies. This well-characterized model is extensively used to study T-cell signaling, apoptosis, and the molecular basis of T-ALL. Jurkat cells express hallmark T-cell markers and respond to extracellular cues, coupled with robust proliferation and genetic manipulability, making them a preferred host for CRISPR-based gene disruption to dissect oncogenic and immunological pathways.
ARID5B is an AT-rich interaction domain transcription factor and chromatin remodeler critical for lymphocyte development and embryonic stem cell pluripotency. It is activated downstream of BMP receptors and SMAD1/5/8 proteins, interacting with the SWI/SNF complex, GTF2I, and GTF2IRD1. Upregulated by TCF3 and BMP signaling, ARID5B transcriptionally regulates MYC and ID2, thereby controlling proliferation and differentiation. Disruption of ARID5B in Jurkat cells may impair these gene regulatory circuits, altering cell cycle progression and survival programs.
In Jurkat T cells, ARID5B knockout is anticipated to disrupt the balance of transcriptional networks that drive leukemic proliferation and apoptosis resistance. By attenuating MYC expression and relieving ID2-mediated differentiation blocks, loss of ARID5B may sensitize cells to apoptotic stimuli or chemotherapeutic agents, mirroring potential therapeutic vulnerabilities in T-ALL. This polyclonal knockout population thus serves as a powerful tool to dissect the contribution of ARID5B to leukemogenesis and to explore BMP/SMAD-dependent oncogenic mechanisms.
These ARID5B knockout Jurkat polyclonal cells are suitable for a wide range of functional studies, including leukemia biology, transcription factor characterization, and drug sensitivity screening. Researchers can perform Western blotting to assess ARID5B and downstream targets, RT-qPCR for transcriptional profiling, flow cytometry for apoptosis and surface markers, and proliferation assays to measure growth. High-throughput drug sensitivity screens can identify synthetic lethal interactions. These applications facilitate elucidation of ARID5B??s function in T-cell signaling and therapy resistance. For further details, please contact Ascent Research.
